How Insulin Works: The Science behind Blood Sugar Regulation

Cazzola Perrier^*
*Correspondence: Cazzola Perrier, Department of Internal Medicine and Gastroenterology, University of Medicine and Pharmacy, Bucharest, Romania, Email:

Keywords

Proinsulin • Hyperinsulinemia • Transmembrane receptor • Insulins

Introduction

Insulin is a hormone central to the regulation of carbohydrate and fat metabolism in the body. Produced by the beta cells of the pancreas, insulin facilitates the uptake of glucose into tissues, thereby reducing blood sugar levels. This hormone's discovery by Frederick Banting and Charles Best in 1921 marked a significant milestone in medical science, offering a lifesaving treatment for diabetes mellitus. This paper explores the intricate mechanisms by which insulin regulates blood sugar levels and the implications of insulin dysfunction. Insulin is synthesized in the pancreas, specifically within the islets of Langerhans, which contain various cell types, including alpha, beta, delta, and PP cells. Beta cells are responsible for the production and secretion of insulin. These cells respond to blood glucose levels, secreting insulin in a pulsatile manner, which is crucial for maintaining glucose homeostasis [1].

Literature Review

The synthesis of insulin begins with the translation of the Insulin Gene (INS) located on chromosome 11, producing a precursor protein called preproinsulin. This molecule undergoes a series of enzymatic cleavages in the endoplasmic reticulum to form proinsulin. Proinsulin is further processed in the Golgi apparatus, where it is cleaved to produce mature insulin and C-peptide, both of which are secreted into the bloodstream. Insulin secretion is primarily regulated by blood glucose levels. When blood glucose levels rise after a meal, glucose enters beta cells via the GLUT2 transporter. This triggers a cascade of events leading to the closure of ATP-sensitive potassium channels, membrane depolarization, and the opening of voltage-dependent calcium channels. The influx of calcium ions prompts the exocytosis of insulin-containing vesicles, releasing insulin into the bloodstream [2].

Once released into the bloodstream, insulin travels to target tissues, such as the liver, muscle, and adipose tissue. Insulin exerts its effects by binding to the insulin receptor, a transmembrane receptor composed of two alpha and two beta subunits. The binding of insulin to the alpha subunits induces a conformational change that activates the intrinsic tyrosine kinase activity of the beta subunits. The activation of the insulin receptor initiates a complex signaling cascade. The key steps include:

Autophosphorylation of the insulin receptor: The beta subunits of the receptor phosphorylate themselves on specific tyrosine residues.

Recruitment of Insulin Receptor Substrates (IRS): Phosphorylated tyrosine residues on the receptor serve as docking sites for IRS proteins, which are then phosphorylated by the receptor.

Activation of PI3K/Akt Pathway: Phosphorylated IRS proteins activate phosphoinositide 3-kinase (PI3K), which converts PIP2 to PIP3. PIP3 recruits and activates Akt (protein kinase B), a crucial mediator of insulin's metabolic actions.

Translocation of GLUT4: One of the primary actions of activated Akt is to promote the translocation of GLUT4 transporters to the cell membrane in muscle and adipose tissue, facilitating glucose uptake from the blood.

Glycogen synthesis: Insulin signaling also promotes glycogen synthesis in the liver and muscle by activating glycogen synthase and inhibiting glycogen phosphorylase.

Lipid metabolism: Insulin promotes lipid synthesis and storage in adipose tissue while inhibiting lipolysis, thereby reducing free fatty acid levels in the blood.

The primary role of insulin is to lower blood glucose levels by promoting the uptake and utilization of glucose by cells. Muscle and adipose tissues play significant roles in this process. In muscle cells, glucose is either used immediately for energy or stored as glycogen. In adipose tissue, glucose is converted to fatty acids and stored as triglycerides. The liver plays a crucial role in maintaining blood glucose levels during fasting and feeding states. In the fed state, insulin inhibits hepatic glucose production by suppressing gluconeogenesis and glycogenolysis. It also promotes glycogen synthesis and glucose storage in the liver. During fasting, reduced insulin levels and increased glucagon secretion promote gluconeogenesis and glycogenolysis to maintain blood glucose levels [3].

Discussion

Type 1 Diabetes Mellitus (T1DM) is characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Patients with T1DM require lifelong insulin therapy to manage blood glucose levels and prevent complications. Type 2 Diabetes Mellitus (T2DM) is characterized by insulin resistance and relative insulin deficiency. Insulin resistance is a condition where target tissues, such as muscle, liver, and adipose tissue, do not respond effectively to insulin. This leads to elevated blood glucose levels and compensatory hyperinsulinemia. Over time, pancreatic beta cells may fail to maintain increased insulin production, resulting in hyperglycemia. Insulin resistance is a hallmark of T2DM and metabolic syndrome. It is associated with various factors, including obesity, physical inactivity, and genetic predisposition. Insulin resistance impairs glucose uptake and utilization, leading to hyperglycemia and dyslipidemia. Chronic hyperinsulinemia, a compensatory response to insulin resistance, can further exacerbate the condition by promoting weight gain and increasing cardiovascular risk [4].

For individuals with T1DM and advanced T2DM, exogenous insulin therapy is essential. Various insulin formulations are available, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins. Insulin therapy aims to mimic natural insulin secretion patterns, with basal insulin providing a steady level and bolus insulin covering meal-related glucose spikes. For individuals with T2DM, several oral antidiabetic agents can help improve insulin sensitivity and glucose control [5]. These include metformin, sulfonylureas, thiazolidinediones, and DPP-4 inhibitors. Metformin, the first-line treatment, works by reducing hepatic glucose production and improving peripheral insulin sensitivity. Lifestyle modifications, including diet and exercise, are crucial in managing insulin resistance and T2DM. A balanced diet rich in whole grains, vegetables, lean proteins, and healthy fats can help maintain blood glucose levels and reduce insulin resistance. Regular physical activity enhances insulin sensitivity, promotes weight loss, and improves overall metabolic health [6].

Conclusion

Insulin plays a vital role in regulating blood sugar levels, ensuring the body functions optimally. Its intricate mechanisms, from synthesis and secretion to receptor binding and signal transduction, highlight the complexity of glucose homeostasis. Understanding these processes is crucial in managing conditions like diabetes mellitus, where insulin dysfunction is a central feature. Advances in insulin therapy and other treatments continue to improve the quality of life for individuals with diabetes, emphasizing the importance of ongoing research and innovation in this field.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Fritzen, Remi, Amy Davies, Miriam Veenhuizen and Matthew Campbell, et al. "Magnesium deficiency and cardiometabolic disease." Nutr 15 (2023): 2355.

Google Scholar, Crossref, Indexed at

2. Salinas, Maria, Maite López-Garrigós, Emilio Flores and Carlos Leiva-Salinas. "Improving diagnosis and treatment of hypomagnesemia." Clin Chem Lab Med 62 (2024): 234-248.

Google Scholar, Crossref, Indexed at

3. Houston, Mark. "The role of magnesium in hypertension and cardiovascular disease." J Clin Hypertens 13 (2011): 843-847.

Google Scholar, Crossref, Indexed at

4. Fiorentini, Diana, Concettina Cappadone, Giovanna Farruggia and Cecilia Prata. "Magnesium: biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency." Nutr 13 (2021): 1136.

Google Scholar, Crossref, Indexed at

5. Reddy, Snigdha T., Sandeep S. Soman and Jerry Yee. "Magnesium balance and measurement." Adv Chronic Kidney Dis 25 (2018): 224-229.

Google Scholar, Crossref, Indexed at

6. Romani, Andrea MP. "Cellular magnesium homeostasis." Arch Biochem 512 (2011): 1-23.

Google Scholar, Crossref, Indexed at